Stock Events

Stock Events

Allarity Therapeutics 

$1.06
0
+$0.02+1.92% Today

Statistics

Day High
1.09
Day Low
1
52W High
-
52W Low
-
Volume
11,775
Avg. Volume
-
Mkt Cap
16.76M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q3 2025
Next
-0.23
-0.22
-0.2
-0.19
Expected EPS
-0.22
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-50.31MNet Income

Analyst Ratings

$9.50Average Price Target
The highest estimate is 9.50.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALLR.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is a leading biopharmaceutical company focusing on cancer treatments, directly competing with Allarity's oncology focus.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that develops cancer drugs, competing in the same therapeutic areas as Allarity.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio of oncology drugs, making it a direct competitor in the cancer treatment market.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a multinational pharmaceutical company with a strong emphasis on oncology, competing in research and development of cancer treatments.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. focuses on the discovery, development, and commercialization of innovative therapeutics in areas including oncology.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is a biotechnology company with a focus on cancer therapeutics, competing in the biopharmaceutical space.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. has a growing oncology portfolio, making it a competitor in the development and marketing of cancer treatments.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC is a global, science-led biopharmaceutical business that develops a range of oncology drugs, competing in the same market as Allarity.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a major player in oncology with a comprehensive portfolio of cancer treatments, directly competing with Allarity Therapeutics.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company is a global healthcare leader that develops oncology products, competing in the pharmaceutical and biotechnology industry.

About

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
ISIN
US0167445008

Listings

XNAS
US
ALLR
BOATS
BOATS
ALLR.BOATS

0 Comments

Share your thoughts

FAQ

What is Allarity Therapeutics stock price today?▼
The current price of ALLR.BOATS is $1.06 USD — it has increased by +1.92% in the past 24 hours. Watch Allarity Therapeutics stock price performance more closely on the chart.
What is Allarity Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Allarity Therapeutics stocks are traded under the ticker ALLR.BOATS.
What is Allarity Therapeutics market cap?▼
Today Allarity Therapeutics has the market capitalization of 16.76M
When is the next Allarity Therapeutics earnings date?▼
Allarity Therapeutics is going to release the next earnings report on May 18, 2026.
What were Allarity Therapeutics earnings last quarter?▼
ALLR.BOATS earnings for the last quarter are -0.19 USD per share, whereas the estimation was -0.23 USD resulting in a +17.39% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Allarity Therapeutics revenue for the last year?▼
Allarity Therapeutics revenue for the last year amounts to 0 USD.
What is Allarity Therapeutics net income for the last year?▼
ALLR.BOATS net income for the last year is -50.31M USD.
When did Allarity Therapeutics complete a stock split?▼
Allarity Therapeutics has not had any recent stock splits.